PI3K Pathway Biomarkers: PIK3CA, PTEN, AKT1 and Beyond

One Pathway, Several Entry Points

PI3K produces the lipid PIP3, which recruits AKT to the membrane for activation; PTEN removes PIP3 and opposes the whole process. Downstream, AKT and mTORC1 drive growth, metabolism and survival.

Because the pathway can be switched on at the receptor, at PI3K, by losing PTEN, or at AKT, no single gene test captures pathway status. Reports often list several findings that need to be weighed together.

PIK3CA Mutations

PIK3CA encodes the p110-alpha catalytic subunit of PI3K. Activating mutations cluster at a few hotspots and are common in breast, endometrial, colorectal, head and neck and cervical cancers.

In hormone-receptor-positive, HER2-negative advanced breast cancer, a PIK3CA activating mutation in tumour tissue or circulating tumour DNA is used to select the PI3K-alpha inhibitor alpelisib. Outside that setting the predictive value is less established.

PTEN Loss

PTEN can be lost by mutation, by deletion, or by reduced protein expression through other mechanisms. These are detected respectively by sequencing, by copy-number analysis and by immunohistochemistry, and they do not always agree.

PTEN loss activates the pathway constitutively and has been explored as a biomarker for AKT inhibitors, but assay standardisation and scoring remain challenges, so the method should always accompany the result.

AKT1 and Other Alterations

The recurrent AKT1 E17K mutation directly activates AKT by changing its membrane binding. It is uncommon but found across breast, endometrial and other cancers. AKT2 and AKT3 amplifications also occur.

In the CAPItello-291 trial, the AKT inhibitor capivasertib with fulvestrant showed benefit in hormone-receptor-positive breast cancer with PIK3CA, AKT1 or PTEN alterations, treating them as a combined pathway-altered group.

Reading a Pathway Report

Note which gene is altered, the specific variant or copy-number change, the assay used, and whether the sample was tissue or blood. A subclonal variant at low allele fraction is not the same as a clonal driver.

Co-occurring alterations matter: for example, concurrent PTEN loss has been associated with reduced benefit from some pathway inhibitors in retrospective analyses.

Key Takeaways

• ·The PI3K pathway can be activated at several points, so no one gene defines its status.
• ·PIK3CA mutation selects alpelisib in HR-positive advanced breast cancer.
• ·PTEN loss is method-dependent (sequencing, copy number, immunohistochemistry).
• ·Capivasertib trials group PIK3CA, AKT1 and PTEN alterations together as pathway-altered.